Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer

被引：0
|
作者：
Sung Gwe Ahn
Yoon Jin Cha
Soon June Bae
Chanik Yoon
Hak Woo Lee
Joon Jeong
机构：
[1] Yonsei University College of Medicine,Department of Surgery, Gangnam Severance Hospital
[2] Yonsei University College of Medicine,Department of Pathology, Gangnam Severance Hospital
来源：
BMC Cancer | / 18卷
关键词：
Tumor-infiltrating lymphocytes; 21-gene recurrence score; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer
    Matikas, Alexios
    Foukakis, Theodoros
    Michalakis, Ilias
    Georgoulias, Vassilis
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (04) : 319 - 326
  • [42] New Approaches to Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer
    Hamilton, Erika P.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (06) : 356 - 358
  • [43] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    G. Hoste
    K. Punie
    H. Wildiers
    B. Beuselinck
    I. Lefever
    E. Van Nieuwenhuysen
    S. N. Han
    P. Berteloot
    N. Concin
    R. Salihi
    I. Vergote
    P. Neven
    Breast Cancer Research and Treatment, 2018, 171 : 131 - 141
  • [44] Prediction of the 21-gene recurrence score by a non-genomic approach in stage I estrogen receptor-positive, HER2-negative breast cancer
    Le Du, F.
    Takeo, F.
    Park, M.
    Hess, K. R.
    Liu, D.
    Jackson, R.
    Mylander, C.
    Rosman, M.
    Raghavendra, A.
    Tafra, L.
    Ueno, N. T.
    ANNALS OF ONCOLOGY, 2020, 31 : S19 - S20
  • [45] Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study
    Llombart-Cussac, Antonio
    Anton-Torres, Antonio
    Rojas, Beatriz
    Andres, Raquel
    Martinez, Noelia
    Rodriguez, Cesar A.
    Marin, Sara
    Puertolas, Teresa
    Gonzalez, Alejandro Falcon
    Fernandez-Murga, Maria Leonor
    Hagen, Carlos
    Ruiz-Borrego, Manuel
    CANCERS, 2023, 15 (05)
  • [46] Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer
    Ji, Jung Hwan
    Bae, Soong June
    Kim, Kyungsoo
    Chu, Chihhao
    Lee, Kyung-A
    Kim, Yoonjung
    Kim, Jee Hung
    Jeong, Joon
    Ahn, Sung Gwe
    NPJ BREAST CANCER, 2022, 8 (01)
  • [47] Clinical utility of the 21-gene Oncotype DX® Recurrence Score® (RS) assay in hormone receptor-positive, HER2-negative breast cancer (BC)
    Lau, A.
    Miller, D.
    Davison, D.
    Rothney, M.
    Borgen, P.
    BREAST, 2017, 32 : S97 - S97
  • [48] Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer
    Chae, Eun Young
    Moon, Woo Kyung
    Kim, Hak Hee
    Kim, Won Hwa
    Cha, Joo Hee
    Shin, Hee Jung
    Choi, Woo Jung
    Han, Wonshik
    Noh, Dong-Young
    Lee, Sae Byul
    Ahn, Sei Hyun
    PLOS ONE, 2016, 11 (06):
  • [49] Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer
    Jung Hwan Ji
    Soong June Bae
    Kyungsoo Kim
    Chihhao Chu
    Kyung-A Lee
    Yoonjung Kim
    Jee Hung Kim
    Joon Jeong
    Sung Gwe Ahn
    npj Breast Cancer, 8
  • [50] Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer
    Kim, Yun Yeong
    Oh, Se Jeong
    Chun, Yong Soon
    Lee, Woon Kee
    Park, Heung Kyu
    PLOS ONE, 2018, 13 (07):
12345